GAO Report Casts Shade On Sunscreen Ingredients' Chances With FDA
This article was originally published in The Rose Sheet
Executive Summary
GAO report requested by leadership of House and Senate committees with oversight of FDA adds evidence behind an argument that the agency's monograph process for sunscreen and other OTC ingredients should be changed substantially to facilitate making more pharmaceutical remedies available nonprescription.
You may also be interested in...
Apotex' Aleve PM Rival Could Have 180-Day Exclusivity As A CGT
US consumers currently don't have access to enough private label/store brand competition for Aleve PM (naproxen/diphenhydramine), the FDA decides in granting Apotex its first OTC ANDA approval with Competitive Generic Therapy designation and eligibility for a type of exclusivity unlike any other previously allowed for OTCs.
Latest Aleve PM Copy Could Have 180-Day Exclusivity From More Competition
US consumers currently don't have access to enough private label/store brand competition for Aleve PM (naproxen/diphenhydramine), FDA decides in granting Apotex its first OTC ANDA approval with Competitive Generic Therapy designation and eligibility for a type of exclusivity unlike any other previously allowed for OTCs.
Economic Adulteration Underscored In GAO Memory Supplements Study
Audit finds two of three memory supplements tested contain none or lower levels of active supplement than stated on labeling. In a report for current and previous ranking minority members of Senate Special Committee on Aging, GAO points to continuing issues with economic adulteration for gingko biloba.